Journal Article
. 2013 Sep;31(29).
doi: 10.1200/JCO.2012.45.0940.

Response-guided neoadjuvant chemotherapy for breast cancer

Gunter von Minckwitz 1 Jens Uwe Blohmer  Serban Dan Costa  Carsten Denkert  Holger Eidtmann  Wolfgang Eiermann  Bernd Gerber  Claus Hanusch  Jörn Hilfrich  Jens Huober  Christian Jackisch  Manfred Kaufmann  Sherko Kümmel  Stefan Paepke  Andreas Schneeweiss  Michael Untch  Dirk Michael Zahm  Keyur Mehta  Sibylle Loibl  
  • PMID: 24002511
  •     92 citations


Purpose: We investigated disease-free survival (DFS) and overall survival (OS) after response-guided neoadjuvant chemotherapy in patients with early breast cancer.

Patients And Methods: We treated 2,072 patients with two cycles of docetaxel, doxorubicin, and cyclophosphamide (TAC) and randomly assigned early responders to four (n = 704) or six (n = 686) additional TAC cycles, and early nonresponders to four cycles of TAC (n = 321) or vinorelbine and capecitabine (NX; n = 301) before surgery.

Results: DFS was longer in early responders receiving TAC × 8 than in those receiving TAC × 6 (hazard ratio [HR], 0.78; 95% CI, 0.62 to 0.97; P = .026), and in early nonresponders receiving TAC-NX than in those receiving TAC × 6 (HR, 0.59; 95% CI, 0.49 to 0.82; P = .001). Exploratory analysis showed that DFS after response-guided chemotherapy (TAC × 8 or TAC-NX) was significantly longer (HR, 0.71; 95% CI, 0.60 to 0.85; P < .003), as was OS (HR, 0.79; 95% CI, 0.63 to 0.99; P = .048), than on conventional chemotherapy (TAC × 6). DFS was longer after response-guided chemotherapy in all hormone receptor-positive tumors (luminal A HR = 0.55, luminal B [human epidermal growth factor receptor 2 (HER2) negative] HR = 0.40, and luminal B [HER2 positive] HR = 0.56), but not in hormone receptor-negative tumors (HER2 positive [nonluminal] HR = 1.01 and triple negative HR = 0.87). Pathologic complete response did not predict these survival effects. pCR predicted an improved DFS in triple-negative (HR = 6.67), HER2-positive (nonluminal; HR 5.24), or luminal B (HER2-negative) tumors (HR = 3.74).

Conclusion: This exploratory analysis suggests that response-guided neoadjuvant chemotherapy might improve survival and is most effective in hormone receptor-positive tumors. If confirmed, the response-guided approach could provide a clinically meaningful advantage for the neoadjuvant over the adjuvant approach in early breast cancer.

Tissue mechanics modulate microRNA-dependent PTEN expression to regulate malignant progression.
Janna K Mouw, Yoshihiro Yui, +10 authors, Valerie M Weaver.
Nat Med, 2014 Mar 19; 20(4). PMID: 24633304    Free PMC article.
Highly Cited.
Combined use of ¹⁸F-FDG PET/CT and MRI for response monitoring of breast cancer during neoadjuvant chemotherapy.
Kenneth E Pengel, Bas B Koolen, +8 authors, Kenneth G A Gilhuijs.
Eur J Nucl Med Mol Imaging, 2014 Apr 30; 41(8). PMID: 24777490
The actual scenario of neoadjuvant chemotherapy of breast cancer in developing country: a report of 80 cases of breast cancer from a tertiary cancer center in India.
Umesh Das, K C Lakshmaiah, +4 authors, Suresh Babu.
J Cancer Res Clin Oncol, 2014 Jun 05; 140(10). PMID: 24894013
Early prediction of therapy responses and outcomes in breast cancer patients using quantitative ultrasound spectral texture.
Ali Sadeghi-Naini, Lakshmanan Sannachi, +7 authors, Gregory J Czarnota.
Oncotarget, 2014 Jun 19; 5(11). PMID: 24939867    Free PMC article.
Gross cystic disease fluid protein 15 (GCDFP-15) expression in breast cancer subtypes.
Silvia Darb-Esfahani, Gunter von Minckwitz, +14 authors, Sibylle Loibl.
BMC Cancer, 2014 Jul 30; 14. PMID: 25070172    Free PMC article.
Chemotherapy in early breast cancer: when, how and which one?
Marcus Schmidt.
Breast Care (Basel), 2014 Sep 02; 9(3). PMID: 25177256    Free PMC article.
Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis.
Xiao-song Chen, Ying Yuan, +3 authors, Kun-wei Shen.
PLoS One, 2014 Sep 24; 9(9). PMID: 25247558    Free PMC article.
Tumor-infiltrating lymphocytes in breast cancer: A new predictor for responses to therapy.
Yasmin Issa-Nummer, Sibylle Loibl, Gunter von Minckwitz, Carsten Denkert.
Oncoimmunology, 2014 Oct 24; 3. PMID: 25340002    Free PMC article.
A Randomized Phase II Trial of Capecitabine Plus Vinorelbine Followed by Docetaxel Versus Adriamycin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy for Breast Cancer.
Changhoon Yoo, Sung-Bae Kim, +9 authors, Woo Kun Kim.
Cancer Res Treat, 2015 Feb 05; 47(3). PMID: 25648092    Free PMC article.
Management of locally advanced breast cancer-perspectives and future directions.
Konstantinos Tryfonidis, Elzbieta Senkus, Maria J Cardoso, Fatima Cardoso.
Nat Rev Clin Oncol, 2015 Feb 11; 12(3). PMID: 25668732
One-Year Neoadjuvant Endocrine Therapy in Breast Cancer.
Orsolya Rusz, András Vörös, +6 authors, Zsuzsanna Kahán.
Pathol Oncol Res, 2015 Mar 11; 21(4). PMID: 25753983
Ki67--no evidence for its use in node-positive breast cancer.
Fabrice Andre, Monica Arnedos, +2 authors, Suzette Delaloge.
Nat Rev Clin Oncol, 2015 Mar 18; 12(5). PMID: 25781576
Adjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guideline.
S Gandhi, G G Fletcher, +4 authors, M E Trudeau.
Curr Oncol, 2015 Apr 08; 22(Suppl 1). PMID: 25848343    Free PMC article.
Is response-guided therapy being applied in the clinical setting? The hepatitis C example.
Jennifer B Harris, Melea A Ward, Phil Schwab.
Am Health Drug Benefits, 2015 May 13; 8(1). PMID: 25964830    Free PMC article.
International Expert Consensus on Primary Systemic Therapy in the Management of Early Breast Cancer: Highlights of the Fifth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2013).
Vito Amoroso, Daniele Generali, +30 authors, Alberto Bottini.
J Natl Cancer Inst Monogr, 2015 Jun 13; 2015(51). PMID: 26063896    Free PMC article.
Impact of biomarker changes during neoadjuvant chemotherapy for clinical response in patients with residual breast cancers.
Yukie Enomoto, Takashi Morimoto, +11 authors, Yasuo Miyoshi.
Int J Clin Oncol, 2015 Sep 05; 21(2). PMID: 26338270
Prognostic Significance of a Complete Response on Breast MRI in Patients Who Received Neoadjuvant Chemotherapy According to the Molecular Subtype.
Eun Sook Ko, Heon Han, +5 authors, Seok Jin Nam.
Korean J Radiol, 2015 Sep 12; 16(5). PMID: 26357493    Free PMC article.
Early prediction of response to neoadjuvant chemotherapy in breast cancer patients: comparison of single-voxel (1)H-magnetic resonance spectroscopy and (18)F-fluorodeoxyglucose positron emission tomography.
Nariya Cho, Seock-Ah Im, +8 authors, Woo Kyung Moon.
Eur Radiol, 2015 Sep 18; 26(7). PMID: 26376886
Attitudes and practice patterns for maintaining relative dose intensity of chemotherapy in outpatient clinics: results of a Japanese web-based survey.
Hitomi Sakai, Noriyuki Katsumata, Genmu Kadokura.
BMC Cancer, 2015 Oct 07; 15. PMID: 26438185    Free PMC article.
Ovarian cancer patients at high risk of BRCA mutation: the constitutional genetic characterization does not change prognosis.
Renaud Sabatier, Elise Lavit, +11 authors, Patrice Viens.
Fam Cancer, 2016 Feb 03; 15(4). PMID: 26833043
Does primary neoadjuvant systemic therapy eradicate minimal residual disease? Analysis of disseminated and circulating tumor cells before and after therapy.
Sabine Kasimir-Bauer, Ann-Kathrin Bittner, +4 authors, Oliver Hoffmann.
Breast Cancer Res, 2016 Feb 13; 18(1). PMID: 26868521    Free PMC article.
Biological network-driven gene selection identifies a stromal immune module as a key determinant of triple-negative breast carcinoma prognosis.
H Bonsang-Kitzis, B Sadacca, +4 authors, F Reyal.
Oncoimmunology, 2016 Mar 05; 5(1). PMID: 26942074    Free PMC article.
Translating neoadjuvant therapy into survival benefits: one size does not fit all.
Leticia De Mattos-Arruda, Ronglai Shen, Jorge S Reis-Filho, Javier Cortés.
Nat Rev Clin Oncol, 2016 Mar 24; 13(9). PMID: 27000962    Free PMC article.
Exploratory Cost-Effectiveness Analysis of Response-Guided Neoadjuvant Chemotherapy for Hormone Positive Breast Cancer Patients.
Anna Miquel-Cases, Valesca P Retèl, +3 authors, Wim H van Harten.
PLoS One, 2016 Apr 29; 11(4). PMID: 27124410    Free PMC article.
miRNA-205 targets VEGFA and FGF2 and regulates resistance to chemotherapeutics in breast cancer.
Y Hu, Y Qiu, +3 authors, J Zhang.
Cell Death Dis, 2016 Jul 01; 7(6). PMID: 27362808    Free PMC article.
Biology and Management of Patients With Triple-Negative Breast Cancer.
Priyanka Sharma.
Oncologist, 2016 Jul 13; 21(9). PMID: 27401886    Free PMC article.
Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426).
Erica T Warner, Karla V Ballman, +5 authors, Ann H Partridge.
Breast Cancer Res Treat, 2016 Jul 28; 159(1). PMID: 27449492    Free PMC article.
Cost-effectiveness and resource use of implementing MRI-guided NACT in ER-positive/HER2-negative breast cancers in The Netherlands.
Anna Miquel-Cases, Lotte M G Steuten, Lisanne S Rigter, Wim H van Harten.
BMC Cancer, 2016 Sep 07; 16. PMID: 27595620    Free PMC article.
Early prediction of pathological outcomes to neoadjuvant chemotherapy in breast cancer patients using automated breast ultrasound.
Xinguang Wang, Ling Huo, +5 authors, Tao Ouyang.
Chin J Cancer Res, 2016 Nov 24; 28(5). PMID: 27877006    Free PMC article.
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
W Fraser Symmans, Caimiao Wei, +17 authors, Gabriel N Hortobagyi.
J Clin Oncol, 2017 Jan 31; 35(10). PMID: 28135148    Free PMC article.
Highly Cited.
Personalized chemotherapy selection for breast cancer using gene expression profiles.
Kaixian Yu, Qing-Xiang Amy Sang, +6 authors, Jinfeng Zhang.
Sci Rep, 2017 Mar 04; 7. PMID: 28256629    Free PMC article.
Normalization of compression-induced hemodynamics in patients responding to neoadjuvant chemotherapy monitored by dynamic tomographic optical breast imaging (DTOBI).
Amir Y Sajjadi, Steven J Isakoff, +9 authors, Stefan A Carp.
Biomed Opt Express, 2017 Mar 09; 8(2). PMID: 28270967    Free PMC article.
Metronomic Chemotherapy for Primary Non-Metastatic Breast Cancer - a Systematic Review of the Literature.
Malgorzata Banys-Paluchowski, Eugen Ruckhäberle, +2 authors, Tanja Fehm.
Geburtshilfe Frauenheilkd, 2017 Mar 24; 77(2). PMID: 28331236    Free PMC article.
Monitoring Neoadjuvant Chemotherapy for Breast Cancer by Using Three-dimensional Subharmonic Aided Pressure Estimation and Imaging with US Contrast Agents: Preliminary Experience.
Kibo Nam, John R Eisenbrey, +5 authors, Flemming Forsberg.
Radiology, 2017 May 04; 285(1). PMID: 28467142    Free PMC article.
Optical Mammography in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy: Individual Clinical Response Index.
Pamela G Anderson, Sirishma Kalli, +4 authors, Sergio Fantini.
Acad Radiol, 2017 May 24; 24(10). PMID: 28532642    Free PMC article.
Additional value of 18F-FDG PET/CT response evaluation in axillary nodes during neoadjuvant therapy for triple-negative and HER2-positive breast cancer.
Mette S van Ramshorst, Suzana C Teixeira, +9 authors, Marie-Jeanne T Vrancken Peeters.
Cancer Imaging, 2017 May 27; 17(1). PMID: 28545563    Free PMC article.
Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.
Tessa G Steenbruggen, Mette S van Ramshorst, +3 authors, Gabe S Sonke.
Drugs, 2017 Jun 16; 77(12). PMID: 28616845
Circulating tumor cells: what we know, what do we want to know about them and are they ready to be used in clinics?
Zuzana Bielčiková, Anna Jakabová, +3 authors, Vladimír Bobek.
Am J Transl Res, 2017 Jul 04; 9(6). PMID: 28670371    Free PMC article.
Recent Advances in the Neoadjuvant Treatment of Breast Cancer.
Gábor Rubovszky, Zsolt Horváth.
J Breast Cancer, 2017 Jul 12; 20(2). PMID: 28690648    Free PMC article.
Adding Adjuvant Systemic Treatment after Neoadjuvant Therapy in Breast Cancer: Review of the Data.
Shetal A Patel, Angela DeMichele.
Curr Oncol Rep, 2017 Jul 25; 19(8). PMID: 28733827
Chemotherapy-Response Monitoring of Breast Cancer Patients Using Quantitative Ultrasound-Based Intra-Tumour Heterogeneities.
Ali Sadeghi-Naini, Lakshmanan Sannachi, +7 authors, Gregory J Czarnota.
Sci Rep, 2017 Sep 06; 7(1). PMID: 28871171    Free PMC article.
MRI and Prediction of Pathologic Complete Response in the Breast and Axilla after Neoadjuvant Chemotherapy for Breast Cancer.
Joseph J Weber, Maxine S Jochelson, +7 authors, Mahmoud El-Tamer.
J Am Coll Surg, 2017 Sep 19; 225(6). PMID: 28919579    Free PMC article.
Advances in the management of HER2-positive early breast cancer.
José Baselga, Robert E Coleman, Javier Cortés, Wolfgang Janni.
Crit Rev Oncol Hematol, 2017 Oct 19; 119. PMID: 29042085    Free PMC article.
Integrated 18F-FDG PET/MRI in breast cancer: early prediction of response to neoadjuvant chemotherapy.
Nariya Cho, Seock-Ah Im, +8 authors, Koung Jin Suh.
Eur J Nucl Med Mol Imaging, 2017 Nov 05; 45(3). PMID: 29101445
Tumor Infiltrating Lymphocytes in Breast Cancer Patients with Progressive Disease during Neoadjuvant Chemotherapy.
Jacques Raphael, S Nofech-Mozes, +2 authors, S Gandhi.
Pathol Oncol Res, 2017 Dec 10; 25(4). PMID: 29222623
The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO.
S Di Cosimo, C Campbell, +18 authors, E de Azambuja.
Eur J Cancer, 2017 Dec 12; 89. PMID: 29227816    Free PMC article.
Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials.
Early Breast Cancer Trialists' Collaborative Group (EBCTCG).
Lancet Oncol, 2017 Dec 16; 19(1). PMID: 29242041    Free PMC article.
Highly Cited. Review.
Is the whole larger than the sum of the parts? Integrated PET/MRI as a tool for response prediction.
Felix M Mottaghy.
Eur J Nucl Med Mol Imaging, 2017 Dec 28; 45(3). PMID: 29279944
Response monitoring of breast cancer patients receiving neoadjuvant chemotherapy using quantitative ultrasound, texture, and molecular features.
Lakshmanan Sannachi, Mehrdad Gangeh, +7 authors, Gregory J Czarnota.
PLoS One, 2018 Jan 04; 13(1). PMID: 29298305    Free PMC article.
Cancer imaging phenomics toolkit: quantitative imaging analytics for precision diagnostics and predictive modeling of clinical outcome.
Christos Davatzikos, Saima Rathore, +22 authors, Despina Kontos.
J Med Imaging (Bellingham), 2018 Jan 18; 5(1). PMID: 29340286    Free PMC article.
Highly Cited.
Dynamic Diffuse Optical Tomography for Monitoring Neoadjuvant Chemotherapy in Patients with Breast Cancer.
Jacqueline E Gunther, Emerson A Lim, +8 authors, Andreas H Hielscher.
Radiology, 2018 Feb 13; 287(3). PMID: 29431574    Free PMC article.
Five-year results of a phase II trial of preoperative 5-fluorouracil, epirubicin, cyclophosphamide followed by docetaxel with capecitabine (wTX) (with trastuzumab in HER2-positive patients) for patients with stage II or III breast cancer.
Frankie Ann Holmes, Beth A Hellerstedt, +11 authors, Joyce O'Shaughnessy.
Cancer Med, 2018 Mar 28; 7(6). PMID: 29582557    Free PMC article.
Identifying an early treatment window for predicting breast cancer response to neoadjuvant chemotherapy using immunohistopathology and hemoglobin parameters.
Quing Zhu, Susan Tannenbaum, +10 authors, Kert Sabbath.
Breast Cancer Res, 2018 Jun 15; 20(1). PMID: 29898762    Free PMC article.
Image Registration for Microwave Tomography of the Breast Using Priors From Nonsimultaneous Previous Magnetic Resonance Images.
Gregory Boverman, Cynthia E L Davis, Shireen D Geimer, Paul M Meaney.
IEEE J Electromagn RF Microw Med Biol, 2018 Sep 15; 2(1). PMID: 30215027    Free PMC article.
Retrospective analysis of concurrent docetaxel and epirubicin neoadjuvant versus adjuvant chemotherapy: Which leads to better outcomes for different subtype breast cancer patients?
Houpu Yang, Lixin Zhou, +11 authors, Yuan Peng.
Medicine (Baltimore), 2018 Oct 07; 97(40). PMID: 30290661    Free PMC article.
Herceptin® (trastuzumab) in HER2-positive early breast cancer: a systematic review and cumulative network meta-analysis.
Florence R Wilson, Megan E Coombes, +7 authors, Chris Cameron.
Syst Rev, 2018 Nov 16; 7(1). PMID: 30428932    Free PMC article.
Systematic Review.
Controversial issues in the neoadjuvant treatment of triple-negative breast cancer.
Amanda Fitzpatrick, Andrew Tutt.
Ther Adv Med Oncol, 2019 Nov 09; 11. PMID: 31700549    Free PMC article.
Neoadjuvant Chemotherapy Plays an Adverse Role in the Prognosis of Grade 2 Breast Cancer.
Xudong Zhu, Jinqi Xue, +7 authors, Yixiao Zhang.
J Cancer, 2019 Nov 19; 10(23). PMID: 31737103    Free PMC article.
Circulating non‑coding RNA‑biomarker potential in neoadjuvant chemotherapy of triple negative breast cancer?
Andrea Ritter, Marc Hirschfeld, +8 authors, Thalia Erbes.
Int J Oncol, 2019 Dec 04; 56(1). PMID: 31789396    Free PMC article.
Role of Capecitabine in Early Breast Cancer.
Asya N Varshavsky-Yanovsky, Lori J Goldstein.
J Clin Oncol, 2019 Dec 06; 38(3). PMID: 31804861    Free PMC article.
Second-harmonic generation directionality is associated with neoadjuvant chemotherapy response in breast cancer core needle biopsies.
Danielle E Desa, Monisha Bhanote, +7 authors, Edward B Brown.
J Biomed Opt, 2019 Aug 29; 24(8). PMID: 31456385    Free PMC article.
Breast Cancer Treatment Response Monitoring Using Quantitative Ultrasound and Texture Analysis: Comparative Analysis of Analytical Models.
Lakshmanan Sannachi, Mehrdad Gangeh, +7 authors, Gregory J Czarnota.
Transl Oncol, 2019 Jul 22; 12(10). PMID: 31325763    Free PMC article.
Triple-negative breast cancer: recent treatment advances.
Alice R T Bergin, Sherene Loi.
F1000Res, 2019 Aug 27; 8. PMID: 31448088    Free PMC article.
Prior to Initiation of Chemotherapy, Can We Predict Breast Tumor Response? Deep Learning Convolutional Neural Networks Approach Using a Breast MRI Tumor Dataset.
Richard Ha, Christine Chin, +7 authors, Sachin Jambawalikar.
J Digit Imaging, 2018 Oct 27; 32(5). PMID: 30361936    Free PMC article.
Early prediction of pathologic response to neoadjuvant treatment of breast cancer: use of a cell-loss metric based on serum thymidine kinase 1 and tumour volume.
Bernhard Tribukait.
BMC Cancer, 2020 May 20; 20(1). PMID: 32423477    Free PMC article.
Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer.
Hee Jeong Kim, Woo Chul Noh, +7 authors, Sei Hyun Ahn.
Breast Cancer Res, 2020 May 29; 22(1). PMID: 32460816    Free PMC article.
Clinical significance of SPRY4-IT1 in efficacy and survival prediction in breast cancer patients undergoing neoadjuvant chemotherapy.
Ang Zheng, Lin Zhang, Xinyue Song, Feng Jin.
Histol Histopathol, 2019 Oct 23; 35(4). PMID: 31638266
Ki-67 response-guided preoperative chemotherapy for HER2-positive breast cancer: results of a randomised Phase 2 study.
Hirofumi Mukai, Takeshi Yamaguchi, +14 authors, Yukari Uemura.
Br J Cancer, 2020 Apr 03; 122(12). PMID: 32238920    Free PMC article.
Evaluation of the Efficacy of Neoadjuvant Chemotherapy for Breast Cancer.
Huan Wang, Xiaoyun Mao.
Drug Des Devel Ther, 2020 Jul 02; 14. PMID: 32606609    Free PMC article.
AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019.
Nina Ditsch, Michael Untch, +42 authors, Achim Wöckel.
Breast Care (Basel), 2019 Sep 29; 14(4). PMID: 31558897    Free PMC article.
Quantitative ultrasound radiomics for therapy response monitoring in patients with locally advanced breast cancer: Multi-institutional study results.
Karina Quiaoit, Daniel DiCenzo, +19 authors, Gregory J Czarnota.
PLoS One, 2020 Jul 28; 15(7). PMID: 32716959    Free PMC article.
Intratumoral Immunotherapy for Early-stage Solid Tumors.
Wan Xing Hong, Sarah Haebe, +4 authors, Ronald Levy.
Clin Cancer Res, 2020 Feb 20; 26(13). PMID: 32071116    Free PMC article.
Early stage triple negative breast cancer: Management and future directions.
Lubna N Chaudhary.
Semin Oncol, 2020 Jun 09; 47(4). PMID: 32507668    Free PMC article.
HER2-positive pure mucinous breast carcinoma: A case report and literature review.
Xingjuan Zhao, Xuan Yang, +3 authors, Keda Yu.
Medicine (Baltimore), 2020 Sep 03; 99(33). PMID: 32871976    Free PMC article.
Transcriptomic and functional pathway features were associated with survival after pathological complete response to neoadjuvant chemotherapy in breast cancer.
Takashi Takeshita, Li Yan, +5 authors, Kazuaki Takabe.
Am J Cancer Res, 2020 Sep 10; 10(8). PMID: 32905537    Free PMC article.
Primary medical therapy and breast conservation treatment: the medical oncology perspective.
Nan Soon Wong.
Gland Surg, 2019 Jan 29; 7(6). PMID: 30687629    Free PMC article.
Addition of Capecitabine in Breast Cancer First-line Chemotherapy Improves Survival of Breast Cancer Patients.
Di Xu, Xiu Chen, +5 authors, Jinhai Tang.
J Cancer, 2019 Feb 06; 10(2). PMID: 30719136    Free PMC article.
Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives.
Rafael Caparica, Matteo Lambertini, +3 authors, Martine Piccart.
Ther Adv Med Oncol, 2019 Mar 06; 11. PMID: 30833989    Free PMC article.
Association of ki67 and tumor marker p53 in locally advanced breast cancer patients and evaluation of response to neoadjuvant chemotherapy: a survey in South Iran.
Dena Firouzabadi, Alireza Rezvani, Amirreza Dehghanian, Laleh Mahmoudi.
Cancer Manag Res, 2019 Aug 03; 11. PMID: 31372050    Free PMC article.
Construction of Nomograms for Predicting Pathological Complete Response and Tumor Shrinkage Size in Breast Cancer.
Shuai Yan, Wenjie Wang, +3 authors, Weiyang Tao.
Cancer Manag Res, 2020 Sep 29; 12. PMID: 32982426    Free PMC article.
The treatment option of progressive disease in breast cancer during neoadjuvant chemotherapy: a single-center experience.
Yurong Zheng, Xiaowen Ding, +6 authors, Yang Yu.
Cancer Biol Ther, 2020 May 19; 21(8). PMID: 32420815    Free PMC article.
miR-205: A Potential Biomedicine for Cancer Therapy.
Neeraj Chauhan, Anupam Dhasmana, +2 authors, Murali M Yallapu.
Cells, 2020 Aug 29; 9(9). PMID: 32854238    Free PMC article.
Early response and pathological complete remission in Breast Cancer with different molecular subtypes: a retrospective single center analysis.
Jin Hong, Jiayi Wu, +6 authors, Kunwei Shen.
J Cancer, 2020 Oct 31; 11(23). PMID: 33123282    Free PMC article.
Quantitative ultrasound radiomics using texture derivatives in prediction of treatment response to neo-adjuvant chemotherapy for locally advanced breast cancer.
Archya Dasgupta, Stephen Brade, +14 authors, Gregory J Czarnota.
Oncotarget, 2020 Nov 05; 11(42). PMID: 33144919    Free PMC article.
The Tumor-Fat Interface Volume of Breast Cancer on Pretreatment MRI Is Associated with a Pathologic Response to Neoadjuvant Chemotherapy.
Hwan-Ho Cho, Minsu Park, +5 authors, Sung Hoon Sim.
Biology (Basel), 2020 Nov 14; 9(11). PMID: 33182628    Free PMC article.
Neoadjuvant chemoradiation and breast reconstruction: the potential for improved outcomes in the treatment of breast cancer.
Niamh O' Halloran, Terri McVeigh, +3 authors, Michael Kerin.
Ir J Med Sci, 2018 Jun 28; 188(1). PMID: 29948462
Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome.
Yeon Hee Park, Samir Lal, +28 authors, Zhengyan Kan.
Nat Commun, 2020 Dec 04; 11(1). PMID: 33268821    Free PMC article.
The role of capecitabine-based neoadjuvant and adjuvant chemotherapy in early-stage triple-negative breast cancer: a systematic review and meta-analysis.
Xingfa Huo, Jinming Li, +5 authors, Jiuda Zhao.
BMC Cancer, 2021 Jan 21; 21(1). PMID: 33468087    Free PMC article.
Neoadjuvant immunotherapy in breast cancer: a paradigm shift?
Elena Fountzila, Michail Ignatiadis.
Ecancermedicalscience, 2021 Feb 13; 14. PMID: 33574892    Free PMC article.
Prognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer.
A Matikas, K Wang, +18 authors, T Foukakis.
ESMO Open, 2021 Mar 14; 6(2). PMID: 33714010    Free PMC article.
Neoadjuvant Chemotherapy of Triple-Negative Breast Cancer: Evaluation of Early Clinical Response, Pathological Complete Response Rates, and Addition of Platinum Salts Benefit Based on Real-World Evidence.
Milos Holanek, Iveta Selingerova, +10 authors, Alexandr Poprach.
Cancers (Basel), 2021 Apr 04; 13(7). PMID: 33808149    Free PMC article.
Early response by MR imaging and ultrasound as predictor of pathologic complete response to 12-week neoadjuvant therapy for different early breast cancer subtypes: Combined analysis from the WSG ADAPT subtrials.
Monika Graeser, Simone Schrading, +19 authors, Ulrike Nitz.
Int J Cancer, 2021 Feb 04;. PMID: 33533487    Free PMC article.